Zoetis (NYSE:ZTS) PT Lowered to $196.00 at The Goldman Sachs Group

Zoetis (NYSE:ZTS) had its price target cut by The Goldman Sachs Group from $223.00 to $196.00 in a research note published on Monday, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Barclays cut their price target on shares of Zoetis from $260.00 to $230.00 and set an overweight rating on the stock in a report on Tuesday, April 23rd. StockNews.com cut shares of Zoetis from a strong-buy rating to a buy rating in a report on Tuesday, February 20th. Stifel Nicolaus cut their price target on shares of Zoetis from $195.00 to $180.00 and set a buy rating on the stock in a report on Tuesday, April 30th. Finally, Piper Sandler reaffirmed an overweight rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Zoetis has an average rating of Buy and an average price target of $211.75.

Zoetis Price Performance

Shares of ZTS stock opened at $164.92 on Monday. The company has a market capitalization of $75.25 billion, a PE ratio of 31.78, a price-to-earnings-growth ratio of 2.57 and a beta of 0.86. The firm has a fifty day simple moving average of $167.64 and a 200-day simple moving average of $178.93. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.31 earnings per share. Equities research analysts anticipate that Zoetis will post 5.77 earnings per share for the current fiscal year.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last quarter. Insiders own 0.16% of the company’s stock.

Institutional Trading of Zoetis

Several institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Zoetis in the fourth quarter valued at approximately $980,646,000. Price T Rowe Associates Inc. MD lifted its stake in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Zoetis in the fourth quarter valued at approximately $242,757,000. Vaughan Nelson Investment Management L.P. acquired a new stake in Zoetis in the third quarter valued at approximately $176,219,000. Finally, CIBC Private Wealth Group LLC lifted its stake in Zoetis by 122.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after acquiring an additional 797,884 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.